8 Stories, 7 about Harrow Inc 1313 approved Programs 21 recruiting Registered trials 8-K Sep 4 Latest SEC filing, period to Sep 4 Sep 22 Latest story
Timeline 7 Pipeline 13 Trials 2
Pipeline by stage
Approved 13
Phase 3 primary completions, next 6 months
All trials by completion date Details
Headquarters Nashville, TN Incorporated Delaware Industry Pharmaceutical Preparations Formerly HARROW HEALTH, INC. (to 2023); Imprimis Pharmaceuticals, Inc. (to 2018); TRANSDEL PHARMACEUTICALS INC (to 2012); Bywater Resources, Inc (to 2007) Also known as Bywater Resources, Inc, Harrow Eye, LLC, HARROW HEALTH, INC., HROW, and 3 more Imprimis Pharmaceuticals, Inc., ImprimisRx NJ LLC, TRANSDEL PHARMACEUTICALS INCHow the company describes itself Harrow develops ophthalmic medications and products for dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other front and back-of-eye conditions. The company is based in North America. source
